Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 May;65(5):727–730. doi: 10.1038/bjc.1992.153

Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.

J F Robertson 1, K Bates 1, D Pearson 1, R W Blamey 1, R I Nicholson 1
PMCID: PMC1977381  PMID: 1534019

Abstract

We have examined two new oestrogen receptor (ER) assays--an enzyme immunoassay (EIA) and an immunocytochemical assay (ICA) in a large series of primary breast tumours to compare their potential as predictors of (1) response to endocrine therapy and (2) survival in patients developing advanced breast cancer. Response to endocrine therapy was categorised at 6 months (UICC criteria). ER-ICA appears the better predictor of response to endocrine therapy than ER-EIA. Combining ICA and EIA results did not improve the prediction of response. With both assays patients with ER positive tumours survived longer from the time of diagnosis of advanced disease than those with ER negative tumours. The predictive power of these assay for progression of disease appears slightly better for the ER-ICA.

Full text

PDF
727

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan S. G., Rodger A., Smyth J. F., Leonard R. C., Chetty U., Forrest A. P. Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed) 1985 Feb 2;290(6465):358–358. doi: 10.1136/bmj.290.6465.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blamey R. W., Bishop H. M., Blake J. R., Doyle P. J., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  3. Campbell F. C., Blamey R. W., Elston C. W., Morris A. H., Nicholson R. I., Griffiths K., Haybittle J. L. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1981 Dec 12;2(8259):1317–1319. doi: 10.1016/s0140-6736(81)91341-6. [DOI] [PubMed] [Google Scholar]
  4. Coombes R. C., Powles T. J., Berger U., Wilson P., McClelland R. A., Gazet J. C., Trott P. A., Ford H. T. Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet. 1987 Sep 26;2(8561):701–703. doi: 10.1016/s0140-6736(87)91071-3. [DOI] [PubMed] [Google Scholar]
  5. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  6. Howat J. M., Harris M., Swindell R., Barnes D. M. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer. 1985 Feb;51(2):263–270. doi: 10.1038/bjc.1985.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Howell A., Barnes D. M., Harland R. N., Redford J., Bramwell V. H., Wilkinson M. J., Swindell R., Crowther D., Sellwood R. A. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984 Mar 17;1(8377):588–591. doi: 10.1016/s0140-6736(84)90995-4. [DOI] [PubMed] [Google Scholar]
  8. Hähnel R., Woodings T., Vivian A. B. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979 Aug;44(2):671–675. doi: 10.1002/1097-0142(197908)44:2<671::aid-cncr2820440238>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  9. Jensen E. V. Hormone dependency of breast cancer. Cancer. 1981 May 15;47(10):2319–2326. doi: 10.1002/1097-0142(19810515)47:10<2319::aid-cncr2820471002>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  10. Johnson P. A., Bonomi P. D., Anderson K. M., Wolter J. M., Bacon L. D., Rossof A. H., Economou S. G. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat Rep. 1983 Jul-Aug;67(7-8):717–720. [PubMed] [Google Scholar]
  11. Kinne D. W., Ashikari R., Butler A., Menendez-Botet C., Rosen P. P., Schwartz M. Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer. 1981 May 15;47(10):2364–2367. doi: 10.1002/1097-0142(19810515)47:10<2364::aid-cncr2820471007>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  12. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  13. Legha S. S., Davis H. L., Muggia F. M. Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med. 1978 Jan;88(1):69–77. doi: 10.7326/0003-4819-88-1-69. [DOI] [PubMed] [Google Scholar]
  14. McClelland R. A., Berger U., Miller L. S., Powles T. J., Coombes R. C. Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol. 1986 Aug;4(8):1171–1176. doi: 10.1200/JCO.1986.4.8.1171. [DOI] [PubMed] [Google Scholar]
  15. McGuire W. L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978 Dec;5(4):428–433. [PubMed] [Google Scholar]
  16. Nicholson R. I., Colin P., Francis A. B., Keshra R., Finlay P., Williams M., Elston C. W., Blamey R. W., Griffiths K. Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers. Cancer Res. 1986 Aug;46(8 Suppl):4299s–4302s. [PubMed] [Google Scholar]
  17. Paterson A. H., Zuck V. P., Szafran O., Lees A. W., Hanson J. Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol. 1982 Oct;18(10):937–943. doi: 10.1016/0277-5379(82)90241-3. [DOI] [PubMed] [Google Scholar]
  18. Stewart J. F., King R. J., Sexton S. A., Millis R. R., Rubens R. D., Hayward J. L. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer. 1981 Apr;17(4):449–453. doi: 10.1016/0014-2964(81)90254-1. [DOI] [PubMed] [Google Scholar]
  19. Stewart J., King R., Hayward J., Rubens R. Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Res Treat. 1982;2(3):243–250. doi: 10.1007/BF01806937. [DOI] [PubMed] [Google Scholar]
  20. Walker K. J., Bouzubar N., Robertson J., Ellis I. O., Elston C. W., Blamey R. W., Wilson D. W., Griffiths K., Nicholson R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res. 1988 Nov 15;48(22):6517–6522. [PubMed] [Google Scholar]
  21. Williams M. R., Todd J. H., Ellis I. O., Dowle C. S., Haybittle J. L., Elston C. W., Nicholson R. I., Griffiths K., Blamey R. W. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer. 1987 Jan;55(1):67–73. doi: 10.1038/bjc.1987.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Williams M. R., Todd J. H., Nicholson R. I., Elston C. W., Blamey R. W., Griffiths K. Survival patterns in hormone treated advanced breast cancer. Br J Surg. 1986 Sep;73(9):752–755. doi: 10.1002/bjs.1800730925. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES